YKYY033
/ Youcare Pharmaceutical Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 27, 2026
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
New P1 trial • Cardiovascular • Venous Thromboembolism
1 to 1
Of
1
Go to page
1